Kevin McCormick, Ph.D.
Scientist II
Quantitative Systems Pharmacology

About Kevin
Dr. McCormick has been a member of the QSP solutions group at Simulations Plus since 2021. During his time at SLP, he has provided biological advisement on the pathophysiological and immune-based drug mechanism of action, which was used to construct a comprehensive QSP model of multiple myeloma. After providing clients with an initial model, funding for this project has since been expanded to include cell therapies including CAR T therapies and immune cell engagers. This MM QSP model was used to understand interindividual variability in pharmacokinetics and responses to anti-cancer drugs and how best to implement such understanding to improve cancer therapy. This work has since been written into two regulatory submissions to the FDA.

Prior to his time at SLP, Dr. McCormick obtained a Ph.D. from the University of Pittsburgh School of Medicine’s Interdisciplinary Biomedical Graduate Program where his work focused on investigating immunotherapy targets in vitro and in vivo solid tumor models. After graduating, Dr. McCormick worked under a USAID funded project, the “Global Evaluation of Microbicide Sensitivities,” where he worked with an interdisciplinary team of modelers, policy makers, physicians and scientists to help prevent the global emergence of drug resistant infectious diseases.